GI CANCERS

According to Allan Pickens, MD, surgery outcomes differ in minority patients and oncology surgeons are researching the issue.

Ipsen plans to seek FDA approval for the NALIRIFOX regimen based on positive results from the phase 3 NAPOLI 3 clinical trial.

Results from bemarituzumab in the phase 2 FIGHT study hint that FGFR2b may be a new target of interest in gastric cancer.

Treatment with pelareorep plus atezolizumab in patients with advanced/metastatic pancreatic ductal adenocarcinoma led to an overall response rate nearly triple than the average which were previously reported in historical control trials.

Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.

Cristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.

Early results from the phase 1 JEWEL-101 study show XB002 is well-tolerated in patients with advanced solid tumors.

Charles J. Schneider, MD, FACP, discusses the next steps in managing and treating patients with anal carcinoma.

The phase 2 DeFianCe study will evaluate the safety and efficacy of DKN-01 combined with bevacizumab and chemotherapy in patients with colorectal cancer vs becazixumab and chemotherapy alone.

The first of 160 patients with gastric or gastroesophageal junction cancer has been recruited for the phase 2 DisTinGuish study. Thirty-two study locations are actively recruiting more patients.

Analysis from the phase 3 CALGB/SWOG-80405 trial reveals that acquired genomic alterations in patients treated with cetuximab in combination with chemotherapy in the first-line were not common.

Findings from the TAS-120-101 study have led the FDA to approve futibatinib for the treatment of patients with FGFR2-positive advanced cholangiocarcinoma.

Andreana Holowatyj, PhD, MSCI, discusses the rationale for her research on the growing increase of early-onset appendiceal cancer in the United States.

Following reports of durable response in a phase 1 study, the combination of onvansertib FOLFIRI, and bevacizumab will be evaluating in a phase 2 study of patients with metastatic colorectal cancer.

A novel FGFR inhibitor, RLY-4008, induced high response rates and encouraging durability in patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement, according to data from the phase 1/2 ReFocus trial presented at the 2022 ESMO Congress.

The FDA has approved durvalumab for the treatment of patients with locally advanced or metastatic biliary tract cancer.

During the Annual Meeting of the International Society of Gastrointestinal Oncology, experts in the field and investigators from pivotal studies will elucidate how these advances can be used to guide treatment, and how to choose between available treatments in specific patient populations.

In an interview with Targeted Oncology, Chen Yuan, MD, further discussed the research on the age-dependent associations and risks for patients with pancreatic cancer.

The phase 3 MAGNOLIA study has begun enrolling patients to examine abelacimab for the treatment of thrombosis associated with cancer.

Two genes to assist in determining primary resistance to immunotherapy for patients with mismatch repair–deficient/microsatellite instability–high gastrointestinal cancers have been identified.

The CRC-PREVENT trial examining the ColonoSight test in colorectal cancer and advanced adenomas has completed enrollment with a diverse patient population.

In findings presented at the ESMO World Congress on Gastrointestinal Cancer 2022, patients with intrahepatic and extrahepatic cholangiocarcinoma who were treated with the durvalumab triplet regimen demonstrated improved overall survival compared with the chemotherapy doublet.

Following an FDA investigational new drug application and protocol approval, the phase 2 study of AMP-270 and rintatolimod in patients with advanced pancreatic cancer has begun.

Charles J. Schneider, MD, FACP, discusses the ways in which the management and care of patients with anal carcinoma has changed over the past decade.

The combination of botensilimab and balstilimab showed robust response rate, durability, and tolerability in a patients with microsatellite stable colorectal cancer.